Quarterly report · Q2
4572.TEDINET S100OSD0
Period2022-01-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥840m | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥2.0bn | 2021-01-01 → 2021-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥430m | 2021-01-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥312m | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥777m | 2021-01-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥306m | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥523m | 2021-01-01 → 2021-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥775m | 2021-01-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥349m | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥781m | 2021-01-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥359m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥534m | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥776m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥359m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥776m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥5.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2021-12-31 | Cons. | Assets |
| Total assets | ¥3.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥792m | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥1.1bn | at 2021-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.4bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥4.3bn | at 2021-12-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.8bn | at 2021-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.8bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.2bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥585m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥963m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥57m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥42m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥166m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥102m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-26.53 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.25 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-42.1 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-62.56 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-39.46 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 84.7% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥286m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥286m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥547m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥553m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥553m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥235m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥922m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥430m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥430m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥145m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 439
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1QuarterInstant | 3213070000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4684699000 | JPY |
| Allowance for doubtful accounts accounts receivable trade | Prior1YearInstant | -342000 | JPY |
| Allowance for doubtful accounts accounts receivable trade | CurrentQuarterInstant | -883000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 877898000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 745905000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 430010000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 430010000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 430010000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | Prior1YTDDuration | 430010000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 145020000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -922360000 | JPY |
| Operating income | Prior1YTDDuration | -777339000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 553498000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 286045000 | JPY |
| Revenues from external customers | CurrentYTDDuration | 839543000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 553498000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 286045000 | JPY |
| Net sales | CurrentYTDDuration | 839543000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 235138000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -547155000 | JPY |
| Operating income | CurrentYTDDuration | -312016000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の4の7第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-08 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第20期第2四半期(自 2022年4月1日 至 2022年6月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | Carna Biosciences, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 吉野公一郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00987 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45720 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Filer name in english | FilingDateInstant | Carna Biosciences, Inc. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |